Continued product innovation has historically supported Thermo Fisher Scientific Inc.’s (NYSE:TMO) pricing power and competitive positioning, particularly in premium laboratory equipment. An even more encouraging development was the recovery in Thermo Fisher Scientific Inc.’s (NYSE:TMO) Analytical Instruments segment, which has faced muted demand over the past two years as biotech funding slowed. Bear CaseDespite the strong quarter, investors should keep expectations in check. Organic revenue growth of 5% marks meaningful progress but remains well below the double-digit growth rates Thermo Fisher Scientific Inc. (NYSE:TMO) generated during the pandemic. Thermo Fisher Scientific Inc. (NYSE:TMO) trades at roughly 22x forward earnings, representing a 15.45% premium to the sector.